Discontinued — last reported Q3 '22

Non-Current Assets

PP&E (Net)

Regeneron Pharmaceuticals PP&E (Net) increased by 1.8% to $3.70B in Q3 2022 compared to the prior quarter. Year-over-year, this metric grew by 9.1%, from $3.40B to $3.70B.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ3 2022Nov 3, 2022

How to read this metric

An increase indicates ongoing investment in physical capacity, whereas a decline may suggest aging assets or a strategy of asset-light operations.

Detailed definition

This metric represents the book value of tangible assets after subtracting accumulated depreciation from the total histo...

Peer comparison

Standard line item for all manufacturing and industrial companies; directly comparable across peers.

Metric ID: property_plant_equipment_net

Historical Data

6 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22
Value$3.36B$3.40B$3.48B$3.56B$3.64B$3.70B
QoQ Change+1.1%+2.5%+2.1%+2.3%+1.8%
YoY Change+8.3%+9.1%
Range$3.36B$3.70B
CAGR+8.2%
Avg YoY Growth+8.7%
Median YoY Growth+8.7%
Current Streak5+ quarters growth

Geographic Breakdown — Rest Of World

View all
SegmentQ4 '22
Rest Of World$803.00M
Total

Rest Of World was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.

Geographic Breakdown — Outside United States

View all
SegmentQ4 '24Q4 '25
Outside United States$715.90M$788.00M
Total

Frequently Asked Questions

What is Regeneron Pharmaceuticals's pp&e (net)?
Regeneron Pharmaceuticals (REGN) reported pp&e (net) of $3.70B in Q3 2022.
How has Regeneron Pharmaceuticals's pp&e (net) changed year-over-year?
Regeneron Pharmaceuticals's pp&e (net) increased by 9.1% year-over-year, from $3.40B to $3.70B.
What does pp&e (net) mean?
The current book value of physical assets after accounting for wear and tear.